Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection

Tina Dewan Mahajan, Roderick Hooker, Lisa Maher, Geri Brown, Andreas Reimold

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Chronic hepatitis C in the setting of rheumatoid arthritis may be an obstacle to optimal management because of potential hepatotoxicity and adverse effects from immune suppression in these patients with a chronic infection. There are no reports in the literature discussing the use of abatacept, a T-cell costimulatory blocker, in patients with chronic hepatitis C. This article is the first report to describe the use of abatacept in 2 patients with rheumatoid arthritis and concomitant hepatitis C with favorable outcome.

Original languageEnglish (US)
Pages (from-to)332-334
Number of pages3
JournalJournal of Clinical Rheumatology
Volume16
Issue number7
DOIs
StatePublished - Oct 2010

Fingerprint

Hepatitis C
Rheumatoid Arthritis
Chronic Hepatitis C
Infection
Therapeutics
T-Lymphocytes
Abatacept

Keywords

  • Abatacept
  • hepatitis C infection
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection. / Mahajan, Tina Dewan; Hooker, Roderick; Maher, Lisa; Brown, Geri; Reimold, Andreas.

In: Journal of Clinical Rheumatology, Vol. 16, No. 7, 10.2010, p. 332-334.

Research output: Contribution to journalArticle

Mahajan, Tina Dewan ; Hooker, Roderick ; Maher, Lisa ; Brown, Geri ; Reimold, Andreas. / Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection. In: Journal of Clinical Rheumatology. 2010 ; Vol. 16, No. 7. pp. 332-334.
@article{531adb946a1b4da99d867f84bb6548d2,
title = "Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection",
abstract = "Chronic hepatitis C in the setting of rheumatoid arthritis may be an obstacle to optimal management because of potential hepatotoxicity and adverse effects from immune suppression in these patients with a chronic infection. There are no reports in the literature discussing the use of abatacept, a T-cell costimulatory blocker, in patients with chronic hepatitis C. This article is the first report to describe the use of abatacept in 2 patients with rheumatoid arthritis and concomitant hepatitis C with favorable outcome.",
keywords = "Abatacept, hepatitis C infection, rheumatoid arthritis",
author = "Mahajan, {Tina Dewan} and Roderick Hooker and Lisa Maher and Geri Brown and Andreas Reimold",
year = "2010",
month = "10",
doi = "10.1097/RHU.0b013e3181f4cd92",
language = "English (US)",
volume = "16",
pages = "332--334",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection

AU - Mahajan, Tina Dewan

AU - Hooker, Roderick

AU - Maher, Lisa

AU - Brown, Geri

AU - Reimold, Andreas

PY - 2010/10

Y1 - 2010/10

N2 - Chronic hepatitis C in the setting of rheumatoid arthritis may be an obstacle to optimal management because of potential hepatotoxicity and adverse effects from immune suppression in these patients with a chronic infection. There are no reports in the literature discussing the use of abatacept, a T-cell costimulatory blocker, in patients with chronic hepatitis C. This article is the first report to describe the use of abatacept in 2 patients with rheumatoid arthritis and concomitant hepatitis C with favorable outcome.

AB - Chronic hepatitis C in the setting of rheumatoid arthritis may be an obstacle to optimal management because of potential hepatotoxicity and adverse effects from immune suppression in these patients with a chronic infection. There are no reports in the literature discussing the use of abatacept, a T-cell costimulatory blocker, in patients with chronic hepatitis C. This article is the first report to describe the use of abatacept in 2 patients with rheumatoid arthritis and concomitant hepatitis C with favorable outcome.

KW - Abatacept

KW - hepatitis C infection

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=78049235054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049235054&partnerID=8YFLogxK

U2 - 10.1097/RHU.0b013e3181f4cd92

DO - 10.1097/RHU.0b013e3181f4cd92

M3 - Article

C2 - 20859223

AN - SCOPUS:78049235054

VL - 16

SP - 332

EP - 334

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 7

ER -